<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2022-06-27 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics." This draft guidance describes FDA's recommendations regarding clinical pharmacology considerations during the development of oligonucleotide therapeutics, including characterizing the potential for QT interval prolongation, performing immunogenicity risk assessment, characterizing the ...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2022-13606</p>
    <p><strong>Publication Date:</strong> 2022-06-27</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2022/06/27/2022-13606/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-draft">https://www.federalregister.gov/documents/2022/06/27/2022-13606/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-draft</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2022-13606</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
